Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles D Burger

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
AMIA ... Annual Symposium Proceedings. AMIA Symposium|May 2, 2023
Improving Patient Selection and Prioritization for Hospital at Home Through Predictive ModelingSatyabrata Pati, Gina E Thompson, Christopher J Mull, et al.
The Lancet. Respiratory Medicine|December 5, 2021
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trialZelalem Temesgen, Charles D Burger, Jason Baker, et al.
Frontiers in Sleep|December 22, 2025
Assessment of sleep quality and sleep disordered breathing among post-hospitalized patients with COVID-19Paula L Castellanos, Parthkumar Satashia, Mantavya Punj, et al.
Annals of the American Thoracic Society|June 2, 2017
A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with LymphangioleiomyomatosisCalvin Lu, Hye-Seung Lee, George P Pappas, et al.
Pulmonary Circulation|July 4, 2017
Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus documentFranck F Rahaghi, Hassan M Alnuaimat, Rana L A Awdish, et al.
Medrxiv : the Preprint Server for Health Sciences|June 27, 2020
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 PneumoniaZelalem Temesgen, Mariam Assi, Paschalis Vergidis, et al.
Pulmonary Circulation|May 6, 2022
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertensionLeslie A Spikes, Abubakr A Bajwa, Charles D Burger, et al.
Respiratory Medicine|August 29, 2025
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertensionSandeep Sahay, Harold Palevsky, Karim El-Kersh, et al.
Mayo Clinic Proceedings|November 6, 2020
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort StudyZelalem Temesgen, Mariam Assi, F N U Shweta, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
AMIA ... Annual Symposium Proceedings. AMIA Symposium|May 2, 2023
Improving Patient Selection and Prioritization for Hospital at Home Through Predictive ModelingSatyabrata Pati, Gina E Thompson, Christopher J Mull, et al.
The Lancet. Respiratory Medicine|December 5, 2021
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trialZelalem Temesgen, Charles D Burger, Jason Baker, et al.
Frontiers in Sleep|December 22, 2025
Assessment of sleep quality and sleep disordered breathing among post-hospitalized patients with COVID-19Paula L Castellanos, Parthkumar Satashia, Mantavya Punj, et al.
Annals of the American Thoracic Society|June 2, 2017
A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with LymphangioleiomyomatosisCalvin Lu, Hye-Seung Lee, George P Pappas, et al.
Pulmonary Circulation|July 4, 2017
Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus documentFranck F Rahaghi, Hassan M Alnuaimat, Rana L A Awdish, et al.
Medrxiv : the Preprint Server for Health Sciences|June 27, 2020
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 PneumoniaZelalem Temesgen, Mariam Assi, Paschalis Vergidis, et al.
Pulmonary Circulation|May 6, 2022
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertensionLeslie A Spikes, Abubakr A Bajwa, Charles D Burger, et al.
Respiratory Medicine|August 29, 2025
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertensionSandeep Sahay, Harold Palevsky, Karim El-Kersh, et al.
Mayo Clinic Proceedings|November 6, 2020
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort StudyZelalem Temesgen, Mariam Assi, F N U Shweta, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
Pageof 9